You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH):山東丹紅製藥的鹽酸特拉唑嗪片獲批上市
格隆匯 04-22 17:06

格隆匯4月22日丨步長製藥(603858.SH)公佈,公司全資子公司山東丹紅製藥有限公司近日收到國家藥品監督管理局核准簽發的關於鹽酸特拉唑嗪片的《藥品註冊證書》。

鹽酸特拉唑嗪片適應症:該品口服給藥適用於輕度或中度高血壓治療,可與噻嗪類利尿劑或其它抗高血壓藥物合用,還可以在其他藥物不適用或無效時單獨使用。品主要降低舒張壓。品口服給藥還適用於良性前列腺增生(BPH)引起的症狀治療。

根據米內網數據2018年至2020年中國(城市公立,城市社區,縣級公立,鄉鎮衞生)樣本醫院年度銷售趨勢顯示,鹽酸特拉唑嗪片(2mg)銷售額依次為1.62億元、1.76億元、1.06億元。

截至2022年3月31日,公司在鹽酸特拉唑嗪片上投入的研發費用約為983.15萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account